Glaukos Corp (GKOS)

Currency in USD
152.72
-2.35(-1.52%)
Closed·
152.72-0.05(-0.03%)
·
Advertisement
Trading near 52-week High
GKOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
143.11156.60
52 wk Range
73.16156.60
Key Statistics
Prev. Close
155.07
Open
154.05
Day's Range
143.11-156.6
52 wk Range
73.16-156.6
Volume
672.33K
Average Volume (3m)
993.52K
1-Year Change
47.1149%
Book Value / Share
11.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GKOS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
159.31
Upside
+4.31%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Glaukos Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 159.31
(+4.31% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Buy---Maintain06/07/2026
H.C. Wainwright
Buy168.00+10.01%-New Coverage06/07/2026
Piper Sandler
Buy165.00+8.04%-Maintain01/07/2026
Needham
Buy150.00-1.78%136.00Maintain17/06/2026
Citi
Buy162.00+6.08%140.00Maintain11/06/2026

Glaukos Corp Earnings Call Summary for Q1/2026

  • Glaukos reported Q1 2026 revenue of $150.6M, up 41% YoY, beating estimates of $137M; EPS of -$0.18 exceeded forecast of -$0.28 by 35.71%.
  • U.S. Glaucoma franchise drove growth with 58% YoY increase; gross margin expanded 120 basis points to 84% amid strong operational execution.
  • Full-year 2026 revenue guidance raised to $620M-$635M from prior $600M-$620M, reflecting confidence in glaucoma and corneal health segments.
  • Stock declined 0.65% to $118.85 in after-hours despite earnings beat; shares deemed overvalued after 52% six-month rally amid rising costs concerns.
  • CEO Burns emphasized growth trajectory through product innovation; management targets cash flow breakeven while expanding iDose TR and Epioxa commercialization.
Last Updated: 29/04/2026, 23:00
Read Full Transcript

Earnings

Latest Release
29/04/2026
EPS / Forecast
-0.18 / -0.28
Revenue / Forecast
150.6M / 137.04M
EPS Revisions
Last 90 days

Compare GKOS to Peers and Sector

Metrics to compare
GKOS
Peers
Sector
Relationship
P/E Ratio
−47.4x−13.1x−0.4x
PEG Ratio
1.07−0.200.00
Price/Book
13.4x4.3x2.6x
Price / LTM Sales
16.3x4.2x3.0x
Upside (Analyst Target)
4.5%61.9%51.5%
Fair Value Upside
Unlock−10.5%8.8%Unlock

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
37.13M63.24%5.68B
Other Institutional Investors
22.03M36.76%3.37B
Public Companies & Retail Investors
0.000.00%0.00
Total
59.16M100.00%9.05B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.48%9,090,0291,390,411
Janus Henderson Group Ltd.9.11%5,348,395818,090

People Also Watch

17.60
ALMU
-3.56%
6.8300
LWLG
-3.67%
91.30
MXL
-4.70%
119.920
AAOI
-1.87%
8.31
POET
-4.48%

FAQ

What Is the Glaukos Corp (NYSE: GKOS) Share Price Today?

The Glaukos Corp stock price today is 152.72 USD.

What Stock Exchange Does Glaukos Corp (GKOS) Trade On?

Glaukos Corp is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Glaukos Corp?

The stock symbol (also called a 'ticker') for Glaukos Corp is "GKOS."

What Is the Current Glaukos Corp Market Capitalisation?

As of today, Glaukos Corp (NYSE: GKOS) market cap is 8.97B USD.

What Is Glaukos Corp's (GKOS) Earnings Per Share (TTM)?

The Glaukos Corp EPS is currently -3.29 (Trailing Twelve Months).

When Is the Next Glaukos Corp Earnings Date?

Glaukos Corp's next earnings report will be released on 29/07/2026.

Is GKOS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Glaukos Corp moving averages and other technical indicators, the daily buy/sell signal for GKOS stock is Strong Buy.

How Many Times Has Glaukos Corp Stock Split?

Glaukos Corp has split 0 times. (See the GKOS stock split history page for full effective split date and price information.)

How Many Employees Does Glaukos Corp Have?

Glaukos Corp has 1094 employees, based on their latest Companies House report.

What is the current trading status of Glaukos Corp (NYSE: GKOS)?

As of 11/07/2026, Glaukos Corp (GKOS) is trading at a share price of 152.72 USD, with a previous close of 155.07 USD. The stock has fluctuated within a day range of 143.11 USD to 156.60 USD, while its 52-week range spans from 73.16 USD to 156.60 USD.

What Is Glaukos Corp (GKOS) Price Target According to Analysts?

The average 12-month price target for Glaukos Corp is 159.31 USD, with a high estimate of 175 USD and a low estimate of 138 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +4.31% Upside potential.

What Is the GKOS Premarket Price?

GKOS's last pre-market stock price is 155.00 USD. The pre-market share volume is 450.00, and the stock has decreased by -0.07, or -0.05%.

What Is the GKOS After Hours Price?

GKOS's last after hours stock price is 152.72 USD, the stock has decreased by -0.05, or -0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.